| Literature DB >> 35155670 |
Cristina Quispe1, Jesús Herrera-Bravo2,3, Zeeshan Javed4, Khushbukhat Khan5, Shahid Raza4, Zehra Gulsunoglu-Konuskan6, Sevgi Durna Daştan7,8, Oksana Sytar9,10, Miquel Martorell11, Javad Sharifi-Rad12, Daniela Calina13.
Abstract
Diabetes is a metabolic disease with multifactorial causes which requires lifelong drug therapy as well as lifestyle changes. There is now growing scientific evidence to support the effectiveness of the use of herbal supplements in the prevention and control of diabetes. Curcumin is one of the most studied bioactive components of traditional medicine, but its physicochemical characteristics are represented by low solubility, poor absorption, and low efficacy. Nanotechnology-based pharmaceutical formulations can help overcome the problems of reduced bioavailability of curcumin and increase its antidiabetic effects. The objectives of this review were to review the effects of nanocurcumin on DM and to search for databases such as PubMed/MEDLINE and ScienceDirect. The results showed that the antidiabetic activity of nanocurcumin is due to complex pharmacological mechanisms by reducing the characteristic hyperglycemia of DM. In light of these results, nanocurcumin may be considered as potential agent in the pharmacotherapeutic management of patients with diabetes.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35155670 PMCID: PMC8828342 DOI: 10.1155/2022/1375892
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Chemical structures of most important curcuminoids.
Figure 2Schematic diagram with the effects of curcumin nanoformulations in diabetes. Abbreviation and symbols: ↑: increase; ↓: decrease; non-HDL-C: non-HDL cholesterol.
Some recent curcumin nanoformulations and beneficial effects on diabetic complications.
| Type of nanoformulations∗ | Method | Encapsulation efficiency (%) | Size (nm) | Beneficial effects | References |
|---|---|---|---|---|---|
| Curcumin nanoparticles loaded in Tween 60 | Solvent evaporation nanoprecipitation | 93 | 40-50 | ↓ Endothelial dysfunction | [ |
| Curcumin-loaded liposomes coated with PEG | Film hydration | 80 | 140 | Anti-inflammatory | [ |
| Curcumin-ZnO complex loaded with chitosan | Solvent evaporation followed by ion gelation | Not reported | 43 | ↓ Blood glucose level maintain normal lipid profile | [ |
| Curcumin-loaded PLGA nanoparticles | Emulsion-diffusion-evaporation | 66 | 237 | Protective effect on inflammatory markers improve lipid metabolisms | [ |
| Curcumin-loaded Pluronic nanomicelles | Nanoprecipitation | 88-91 | 333 | ↑ | [ |
| Curcumin-loaded PLA-PEG nanoparticles | Emulsion-diffusion-evaporation | 98 | 117 | Protective effect on liver inflammation | [ |
| Curcumin-loaded PLGA nanoparticles | Emulsion-diffusion-evaporation | 56 | 282 | Delaying diabetic cataracts | [ |
| Curcumin-loaded nanoparticles coated with chitosan | Ion crosslinking | 77 | 91 | ↑ Healing of diabetic wounds | [ |
| Curcumin nanoparticles within QPAMAM (G3) | Emulsion solvent evaporation | Not reported | 40 | Preventing oxidant mediated diabetic cataract development | [ |
| Curcumin-encapsulated PBLG-PEG-PBLG nanocapsules | Ring-opening polymerization | 32 | 30 | ↓ Diabetic cardiomyopathy | [ |
Abbreviations and symbols: ↑: increase; ↓: decrease; PLA: polylactic acid; PEG: polyethylene glycol; PBLG: poly(gamma-benzyl l-glutamate); QPAMAM (G3): quaternary ammonium poly(amidoamine) dendrimer.